<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959295</url>
  </required_header>
  <id_info>
    <org_study_id>M522101-J11</org_study_id>
    <nct_id>NCT01959295</nct_id>
  </id_info>
  <brief_title>Phase III Study of ASP2151 in Herpes Simplex Patients</brief_title>
  <official_title>Phase III Study of ASP2151 in Herpes Simplex Patients ― A Double-blind, Placebo-controlled Study ―</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Co., Ltd.</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, placebo-controlled, parallel-group study will be conducted to
      evaluate the efficacy and safety of ASP2151 in patients with herpes simplex (labial/facial
      herpes or recurrent genital herpes). The efficacy will be evaluated for the primary endpoint
      defined as, &quot;the proportion of subjects achieving lesion healing by Day 8 of study treatment&quot;
      to demonstrate the superiority of ASP2151 to placebo. The safety will be evaluated based on
      adverse events, laboratory tests, vital signs, and ECGs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving lesion healing by Day 8 of study treatment</measure>
    <time_frame>8days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to healing</measure>
    <time_frame>29days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete crusting</measure>
    <time_frame>29days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virus disappearance</measure>
    <time_frame>29days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">453</enrollment>
  <condition>Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>ASP2151</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2151 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151</intervention_name>
    <description>200 mg once daily</description>
    <arm_group_label>ASP2151</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151 placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>ASP2151 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a rash associated with moderate or severe herpes simplex, for which oral
             antiviral medication is indicated

               -  Labial/facial herpes: Patients with at least 10 papulae or vesicles/pustules

               -  Recurrent genital herpes: Patients with at least 5 papulae or vesicles/pustules
                  on the genital organs or in the genital and circumanal region

          2. Patients who can start receiving the study drug within 48 hours after onset of rash

          3. Age: 20 years or older, but younger than 80 years

        Exclusion Criteria:

          1. Patients who are not expected to have an adequate response to oral antiviral
             medication

          2. An extreme decline in immune function

          3. Presence of serious complications

          4. Patients found to meet any of the following conditions based on laboratory tests
             performed within 14 days before informed consent:

               -  AST or ALT ≥ 2.5 x upper limit of normal

               -  Platelet count &lt; lower limit of normal

               -  Serum creatinine ≥ 1.5 mg/dL

               -  Creatinine clearance &lt; 30 mL/min

          5. Current or previous history of malignant tumor within 5 years before informed consent

          6. Diagnosis of autoimmune disease

          7. Evidence of bone marrow suppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

